CY1119880T1 - Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων - Google Patents
Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεωνInfo
- Publication number
- CY1119880T1 CY1119880T1 CY20181100131T CY181100131T CY1119880T1 CY 1119880 T1 CY1119880 T1 CY 1119880T1 CY 20181100131 T CY20181100131 T CY 20181100131T CY 181100131 T CY181100131 T CY 181100131T CY 1119880 T1 CY1119880 T1 CY 1119880T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- pharmaceutically acceptable
- methods
- pyrosolopyrimidine
- products
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μεθόδους και συνθέσεις για την αναστολή ιικών πολυμεράσεων νουκλεϊκού οξέος, όπως ιικών RNA ή DNA πολυμεράσεων, και μεθόδους και συνθέσεις που είναι χρήσιμες για τη θεραπεία ιικών λοιμώξεων σε υποκείμενα. Οι μέθοδοι περιλαμβάνουν τη χορήγηση στο υποκείμενο μίας θεραπευτικώς αποτελεσματικής ποσότητας ενός συμπλόκου του τύπου I ή ενός φαρμακευτικώς αποδεκτού άλατος ή ένυδρου άλατος αυτού ή μιας σύνθεσης που περιλαμβάνει μια ένωση του τύπου I ή ενός φαρμακευτικώς αποδεκτού άλατος ή ένυδρου άλατος αυτής και ενός φαρμακευτικώς αποδεκτού φορέα. Η σύνθεση ή μέθοδος μπορεί προαιρετικά να συνδυάζει έναν ή περισσότερους πρόσθετους αντι-ιικούς παράγοντες.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39352210P | 2010-10-15 | 2010-10-15 | |
| US201161492054P | 2011-06-01 | 2011-06-01 | |
| EP11833515.7A EP2627334B1 (en) | 2010-10-15 | 2011-10-14 | Compositions for use in the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119880T1 true CY1119880T1 (el) | 2018-06-27 |
Family
ID=45938737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100131T CY1119880T1 (el) | 2010-10-15 | 2018-02-02 | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US20130331404A1 (el) |
| EP (3) | EP2898885B1 (el) |
| JP (2) | JP5902698B2 (el) |
| KR (1) | KR101850925B1 (el) |
| CN (1) | CN103429245B (el) |
| AU (2) | AU2011315902B2 (el) |
| BR (1) | BR112013009029B1 (el) |
| CA (1) | CA2813783C (el) |
| CY (1) | CY1119880T1 (el) |
| DK (2) | DK2627334T3 (el) |
| ES (2) | ES2536831T3 (el) |
| HK (2) | HK1212914A1 (el) |
| HR (2) | HRP20150487T1 (el) |
| HU (1) | HUE036387T2 (el) |
| IL (1) | IL225672B (el) |
| LT (1) | LT2898885T (el) |
| MX (1) | MX348759B (el) |
| PL (2) | PL2627334T3 (el) |
| PT (2) | PT2627334E (el) |
| RS (2) | RS56870B1 (el) |
| RU (3) | RU2599013C2 (el) |
| SI (2) | SI2627334T1 (el) |
| SM (1) | SMT201500148B (el) |
| WO (1) | WO2012051570A1 (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009240630B2 (en) | 2008-04-23 | 2013-07-18 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| KR101848099B1 (ko) | 2009-09-21 | 2018-04-11 | 길리애드 사이언시즈, 인코포레이티드 | 1'-치환된 카바-뉴클레오사이드 유사체의 제조를 위한 방법 및 중간체 |
| EP2596004B1 (en) | 2010-07-19 | 2014-09-10 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| BR112013001553B1 (pt) | 2010-07-22 | 2021-01-12 | Gilead Sciences, Inc. | compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem |
| RS56870B1 (sr) * | 2010-10-15 | 2018-04-30 | Biocryst Pharm Inc | Pirolopirimidinski derivati za primenu u lečenju virusnih infekcija |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| CA2890905A1 (en) * | 2012-11-16 | 2014-05-22 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
| EP2996685B1 (en) * | 2013-05-14 | 2019-03-27 | Biocryst Pharmaceuticals, Inc. | Anti-influenza compositions and methods |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| CN104513249B (zh) * | 2014-12-26 | 2016-08-31 | 苏州明锐医药科技有限公司 | 抗埃博拉病毒药物bcx4430的制备方法 |
| PL3785717T3 (pl) | 2015-09-16 | 2022-05-02 | Gilead Sciences, Inc. | Sposoby leczenia infekcji coronaviridae |
| MX2018010707A (es) * | 2016-03-06 | 2019-03-28 | Biocryst Pharm Inc | Métodos y composiciones para el tratamiento de la infección por el virus del zika. |
| DE102016002873A1 (de) | 2016-03-09 | 2016-05-25 | Heinz Kiefer | Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind |
| EP3595672B1 (en) | 2017-03-14 | 2023-09-06 | Gilead Sciences, Inc. | Compounds for use in methods of treating feline coronavirus infections |
| AR111490A1 (es) | 2017-05-01 | 2019-07-17 | Gilead Sciences Inc | Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino) |
| TW201919648A (zh) | 2017-07-11 | 2019-06-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物 |
| US20220273689A1 (en) * | 2019-07-09 | 2022-09-01 | Regents Of The University Of Minnesota | Potentiation of antiviral nucleobases as rna virus therapy |
| KR20220132608A (ko) | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
| TW202309061A (zh) | 2020-03-12 | 2023-03-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| US20230158054A1 (en) * | 2020-04-07 | 2023-05-25 | Biocryst Pharmaceuticals, Inc. | Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections |
| AU2021281351A1 (en) | 2020-05-29 | 2023-01-19 | Gilead Sciences, Inc. | Remdesivir treatment methods |
| BR112022026321A2 (pt) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | Análogos de 1'-ciano nucleosídeo e usos dos mesmos |
| KR20230057411A (ko) | 2020-08-27 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| EP4360629A1 (en) * | 2021-06-25 | 2024-05-01 | Industry Foundation of Chonnam National University | Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections |
| EP4387733A1 (en) * | 2021-08-17 | 2024-06-26 | Southwest Research Institute | Inhibitors for coronavirus |
| EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9520364D0 (en) * | 1995-10-05 | 1995-12-06 | Chiroscience Ltd | Compouundds |
| US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| US6228741B1 (en) | 1998-01-13 | 2001-05-08 | Texas Instruments Incorporated | Method for trench isolation of semiconductor devices |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US7098334B2 (en) | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| US20050250728A1 (en) * | 2002-05-23 | 2005-11-10 | Shanta Bantia | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
| WO2006002231A1 (en) * | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| US7514410B2 (en) * | 2005-03-29 | 2009-04-07 | Biocryst Pharmaceuticals, Inc. | Hepatitis C therapies |
| US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
| SI2057165T1 (sl) | 2006-09-07 | 2011-07-29 | Ind Res Ltd Gracefield Res Ct | Acikliäśni aminski zaviralci nukleozidnih fosforilaz in hidrolaz |
| EA016830B1 (ru) | 2006-09-11 | 2012-07-30 | Саузерн Рисерч Инститьют | Азольные нуклеозиды и их применение в качестве ингибиторов вариальных рнк- и днк-полимераз |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| RS56870B1 (sr) | 2010-10-15 | 2018-04-30 | Biocryst Pharm Inc | Pirolopirimidinski derivati za primenu u lečenju virusnih infekcija |
| NZ609309A (en) * | 2010-11-11 | 2015-04-24 | Redx Pharma Plc | Redox drug derivatives |
| AR090699A1 (es) | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2011
- 2011-10-14 RS RS20180135A patent/RS56870B1/sr unknown
- 2011-10-14 RU RU2013121794/15A patent/RU2599013C2/ru active
- 2011-10-14 RS RS20150369A patent/RS54072B1/en unknown
- 2011-10-14 CA CA2813783A patent/CA2813783C/en active Active
- 2011-10-14 SI SI201130489T patent/SI2627334T1/sl unknown
- 2011-10-14 MX MX2013003938A patent/MX348759B/es active IP Right Grant
- 2011-10-14 JP JP2013534046A patent/JP5902698B2/ja active Active
- 2011-10-14 HU HUE14198125A patent/HUE036387T2/hu unknown
- 2011-10-14 DK DK11833515.7T patent/DK2627334T3/en active
- 2011-10-14 SI SI201131383T patent/SI2898885T1/en unknown
- 2011-10-14 US US13/879,110 patent/US20130331404A1/en not_active Abandoned
- 2011-10-14 PT PT118335157T patent/PT2627334E/pt unknown
- 2011-10-14 PL PL11833515T patent/PL2627334T3/pl unknown
- 2011-10-14 EP EP14198125.8A patent/EP2898885B1/en active Active
- 2011-10-14 KR KR1020137012318A patent/KR101850925B1/ko active IP Right Grant
- 2011-10-14 ES ES11833515.7T patent/ES2536831T3/es active Active
- 2011-10-14 PT PT141981258T patent/PT2898885T/pt unknown
- 2011-10-14 DK DK14198125.8T patent/DK2898885T3/en active
- 2011-10-14 BR BR112013009029-4A patent/BR112013009029B1/pt active IP Right Grant
- 2011-10-14 EP EP17196354.9A patent/EP3345605B1/en active Active
- 2011-10-14 CN CN201180059786.9A patent/CN103429245B/zh active Active
- 2011-10-14 AU AU2011315902A patent/AU2011315902B2/en active Active
- 2011-10-14 ES ES14198125.8T patent/ES2657687T3/es active Active
- 2011-10-14 RU RU2016134401A patent/RU2718690C2/ru active
- 2011-10-14 LT LTEP14198125.8T patent/LT2898885T/lt unknown
- 2011-10-14 EP EP11833515.7A patent/EP2627334B1/en active Active
- 2011-10-14 PL PL14198125T patent/PL2898885T3/pl unknown
- 2011-10-14 WO PCT/US2011/056421 patent/WO2012051570A1/en active Application Filing
-
2013
- 2013-04-10 IL IL225672A patent/IL225672B/en active IP Right Grant
-
2014
- 2014-11-03 US US14/531,471 patent/US9492452B2/en active Active
-
2015
- 2015-05-06 HR HRP20150487TT patent/HRP20150487T1/hr unknown
- 2015-06-25 SM SM201500148T patent/SMT201500148B/xx unknown
-
2016
- 2016-01-28 HK HK16100950.0A patent/HK1212914A1/zh unknown
- 2016-03-10 JP JP2016046875A patent/JP2016135790A/ja not_active Withdrawn
- 2016-10-28 US US15/337,320 patent/US10022375B2/en active Active
-
2017
- 2017-01-24 AU AU2017200471A patent/AU2017200471B2/en active Active
-
2018
- 2018-02-02 CY CY20181100131T patent/CY1119880T1/el unknown
- 2018-02-06 HR HRP20180220TT patent/HRP20180220T1/hr unknown
- 2018-06-20 US US16/013,059 patent/US10420769B2/en active Active
- 2018-12-25 HK HK18116571.3A patent/HK1257363A1/zh unknown
-
2019
- 2019-08-16 US US16/543,079 patent/US11173159B2/en active Active
-
2020
- 2020-03-17 RU RU2020111042A patent/RU2020111042A/ru unknown
-
2021
- 2021-10-21 US US17/506,836 patent/US20220040190A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| CY1123324T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
| EA201401281A1 (ru) | D-аминокислотные химические соединения для лечения заболеваний печени | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
| EA200901241A1 (ru) | Соединения для лечения гепатита с | |
| EA201491180A1 (ru) | 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с | |
| CY1122074T1 (el) | Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις | |
| BR112012033117A2 (pt) | pirazolo[1,5-a]pirimidinas como agentes antivirais | |
| BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
| EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
| EA201391519A1 (ru) | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний | |
| EA201001508A1 (ru) | Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич | |
| EA201100928A1 (ru) | Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| WO2011150190A3 (en) | Hcv inhibitor compounds and methods of use thereof | |
| CY1121334T1 (el) | Αναστολεας κινασης aurora a | |
| CY1117504T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1 |